Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Leuko Labs is a medical technology company at the forefront of hematology innovation. They are dedicated to developing PointCheck™, the world's first non-invasive device for monitoring white blood cell levels. This breakthrough technology aims to significantly improve the quality of life and treatment outcomes for immunosuppressed patients, such as those undergoing chemotherapy, by enabling convenient and frequent monitoring without the need for blood draws. Their mission is to empower patients and clinicians with actionable health insights, reducing risks of infection and hospitalizations.
The headquarters serves as the primary center for research and development, engineering, clinical trial management, and corporate operations for Leuko Labs.
Located in Kendall Square, offering proximity to MIT, renowned research institutions, and a vibrant ecosystem of startups and established life science companies. The facilities likely include advanced laboratories for device development and testing.
Leuko Labs fosters an innovative, collaborative, and mission-driven work environment. The culture emphasizes scientific rigor, patient-centric solutions, and a fast-paced startup dynamism, attracting talent passionate about making a tangible impact in healthcare.
Its Cambridge location is highly significant, providing access to top-tier talent, cutting-edge research, potential strategic partnerships, and venture capital, all crucial for a medical technology company's growth and success.
While Leuko Labs is headquartered and currently focuses its primary operations in the United States, its innovative PointCheck™ technology for non-invasive white blood cell monitoring addresses a universal healthcare need. The company's vision is global, aiming to eventually bring its solution to immunosuppressed patients worldwide. Future global presence will likely involve strategic partnerships for distribution, regulatory approvals in different regions (e.g., Europe, Asia), and participation in international clinical studies.
245 Main Street
Cambridge
MA
USA
Address: Operations are centralized at 245 Main Street, Cambridge, MA
The primary focus is on leveraging the Boston/Cambridge biotech ecosystem for innovation and initial market development in North America.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Leuko' leadership includes:
Leuko has been backed by several prominent investors over the years, including:
Public information and news searches over the last 12 months do not indicate significant C-suite level new hires or departures at Leuko Labs. The company's founding leadership team appears to remain consistent as they advance their PointCheck™ technology.
Discover the tools Leuko uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for technology and life science companies like Leuko Labs often utilize patterns such as first initial followed by last name, or first name separated from last name by a dot, all preceding '@leukolabs.com'. The exact internal convention isn't publicly specified.
[first_initial][last]@leukolabs.com (e.g., jdoe@leukolabs.com) or [first].[last]@leukolabs.com (e.g., jane.doe@leukolabs.com)
Format
ccastrogonzalez@leukolabs.com (speculative example for Carlos Castro-Gonzalez based on a common format)
Example
70%
Success rate
Leuko Labs News / NASA • November 16, 2023
Leuko Labs was awarded first place at the 2023 NASA iTech Cycle II Forum for its innovative PointCheck™ technology, highlighting its potential impact and application in various environments, including space exploration....more
Leuko Labs News / PR Newswire • September 19, 2023
Leuko Labs received a significant Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). This funding supports the further validation of its PointCheck™ device in chemotherapy patients, a critical step towards clinical adoption....more
MedTech Innovator • May 23, 2023
Leuko Labs was chosen as one of the 61 companies for the 2023 Cohort of MedTech Innovator, the world’s largest accelerator of medical technology companies. This selection recognized Leuko Labs' potential to transform healthcare with its non-invasive white blood cell monitoring technology....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Leuko, are just a search away.